Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) reported positive top line data from an open label exploratory Phase II FAB-C clinical trial assessing ZYN002 cannabidiol gel in pediatric and adolescent people with Fragile X syndrome. The study successfully achieved its primary endpoint, recording a 46% improvement in the total score of ADAMS at week twelve as against baseline. ZYN002 also recorded clinically meaningful improvements in distinct measures of the ABC-FXS, which address the major symptoms of FXS including temper tantrums, repetitive movements, hyperactivity and social avoidance.
Steven Siegel of Keck School of Medicine of USC, expressed that the results from the FAB-C study are extremely exciting and showcase that ZYN002 may have a deep effect on improving several disabling symptoms of Fragile X, like anxiety and difficult behaviors.
Fragile X is a tough genetic autism spectrum disorder, with intricate symptomatology that considerably impacts patients and their families. Several kids with Fragile X and their families combat with the lack of approved medications to safely cure their indications. This study indicates that ZYN002 is ready for the subsequent phase of development, and he consider that this drug shows great promise as a prospective treatment for these extremely difficult-to-treat symptoms.
With these results, Zynerba expects that it will meet with the U.S. FDA in 1H2018 with an objective of moving quickly into a major Phase 2/3 program in adolescent and pediatric patients with FXS in 2018. The U.S.FDA has allowed Zynerba Orphan Drug designation for the application of Cannabinoid as treatment of people with FXS.
Orphan Drug status is granted to novel medications that treat a rare condition or disease affecting fewer than 200,000 patients in the United States, and offers benefits including a 7-year period of United States marketing exclusivity upon marketing nod for the designated indication and may offer a fast path to market authorization.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.